– USA, PA –  Palladio Biosciences, Inc., a private biopharmaceutical company founded to develop medicines that make a meaningful impact on the lives of patients with orphan diseases of the kidney, announced today the appointment of Sanford Zweifach as the Company’s first Chairman of the Board of Directors.

“I am very excited to welcome Sandy as the new Chairman of our Board of Directors. He brings an exceptional combination of operational, financing and deal experience to Palladio Biosciences,” said Lorenzo Pellegrini, Ph.D., President and Chief Executive Officer of Palladio. “His leadership and unique combination of skills will be incredibly valuable resources as we continue to build Palladio Biosciences into a leading drug development company dedicated to renal orphan diseases.”

About Sanford Zweifach

Mr. Zweifach brings to Palladio over 25 years’ experience in senior executive roles in the life sciences industry, with a focus in corporate partnering, business development, operations, private and public investing, and capital raising. He is the Co-Founder and Chief Executive Officer of Nuvelution Pharma, Inc. Previously, Mr. Zweifach was the Co-founder and CEO of Ascendancy Healthcare, Inc. He has also been a Partner at Reedland Capital Partners, CEO of Pathways Diagnostics, Managing Director and CFO of Bay City Capital, and President and CFO of Epoch Biosciences, which was acquired by Nanogen. He currently serves as the Chair of IMIDomics SL and Non-Executive Board Member of Compugen, Inc. (NASDAQ: CGEN) and Realm Therapeutics, Inc. He received his BA in Biology from UC San Diego and an MS in Human Physiology from UC Davis.

“I look forward to working together with Lorenzo and the entire Board of Palladio,” added Mr. Zweifach. “Palladio’s lixivaptan has enormous potential to address the large unmet medical needs of patients with orphan diseases of the kidney, and I am delighted to assist in bringing together the necessary elements to further develop the opportunity.”

About Palladio Biosciences, Inc.

Palladio Biosciences is a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney and is located near Philadelphia, PA. Palladio is initially developing its lead drug, lixivaptan, for Polycystic Kidney Disease, an orphan kidney disease for which there are limited treatment options.

For more information : http://palladiobio.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.